📊 BQST Key Takeaways
Is Bioquest Corp (BQST) a Good Investment?
Bioquest Corp exhibits severe financial distress with negative stockholders' equity of -$536.4K, indicating the company is technically insolvent. Revenue generation is minimal at $31K while operating losses reach -$49.7K, demonstrating the company cannot sustain operations. Critically low liquidity (0.03x current ratio) combined with negative operating and free cash flows (-$29K) suggests imminent operational collapse.
Bioquest Corp's fundamentals indicate a severely distressed business: revenue is negligible, operating and net margins are deeply negative, and the company is consuming cash with no sign of a sustainable profit engine. The balance sheet is exceptionally weak, with negative equity, extremely poor liquidity, and liabilities that vastly exceed assets, while the latest available data is also stale, increasing uncertainty rather than supporting a recovery case.
Why Buy Bioquest Corp Stock? BQST Key Strengths
- Minimal long-term debt burden (N/A long-term debt)
- Net loss improved year over year, suggesting some reduction in bottom-line deterioration
- Operating cash burn is relatively small in absolute dollars, which may modestly slow near-term cash depletion
- The company carries a very small asset base and limited capital expenditure requirements
BQST Stock Risks: Bioquest Corp Investment Risks
- Negative stockholders' equity of -$536.4K indicating technical insolvency
- Severe liquidity crisis with current ratio of 0.03x and negative quick ratio
- Unsustainable operations with negative operating margin of -160.4% and net margin of -398.5%
- Cash burn rate exceeds revenue generation by 10x with operating cash flow of -$18.6K
- Minimal revenue base of only $31K suggests inability to support operations
- Deteriorating net income trending worse year-over-year (+64.7% loss increase)
- Zero insider transactions in past 90 days indicating potential abandonment
- Stale data from July 2022 raises concerns about current company status
- Negative stockholders' equity and a 0.03x current ratio indicate acute financial stress and potential going-concern risk
- Revenue base is extremely small relative to losses, indicating weak business scale and poor growth quality
- Free cash flow is negative and assets consist almost entirely of minimal cash, leaving little financial flexibility
Key Metrics to Watch
- Stockholders' equity recovery trajectory
- Cash position sustainability and burn rate
- Operating revenue growth and path to positive margins
- Total liabilities reduction progress
- Operating cash flow improvement and cash runway remaining
- Quarterly revenue growth and whether sales become large enough to support fixed costs
- Liquidity runway, especially cash balance versus current liabilities and any improvement in stockholders' equity
Bioquest Corp (BQST) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BQST Profit Margin, ROE & Profitability Analysis
BQST vs Healthcare Sector: How Bioquest Corp Compares
How Bioquest Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Bioquest Corp Stock Overvalued? BQST Valuation Analysis 2026
Based on fundamental analysis, Bioquest Corp has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Bioquest Corp Balance Sheet: BQST Debt, Cash & Liquidity
BQST Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Bioquest Corp's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.28 indicates the company is currently unprofitable.
BQST Revenue Growth, EPS Growth & YoY Performance
BQST Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2015 | N/A | $286 | N/A |
| Q2 2015 | N/A | -$3.3K | N/A |
| Q1 2015 | N/A | -$5.0K | N/A |
| Q3 2014 | N/A | $286 | N/A |
| Q2 2014 | N/A | -$3.3K | N/A |
| Q1 2014 | N/A | -$259 | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Bioquest Corp Dividends, Buybacks & Capital Allocation
BQST SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Bioquest Corp (CIK: 0001568628)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BQST
What is the AI rating for BQST?
Bioquest Corp (BQST) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 95% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BQST's key strengths?
Claude: Minimal long-term debt burden (N/A long-term debt). ChatGPT: Net loss improved year over year, suggesting some reduction in bottom-line deterioration. Operating cash burn is relatively small in absolute dollars, which may modestly slow near-term cash depletion.
What are the risks of investing in BQST?
Claude: Negative stockholders' equity of -$536.4K indicating technical insolvency. Severe liquidity crisis with current ratio of 0.03x and negative quick ratio. ChatGPT: Negative stockholders' equity and a 0.03x current ratio indicate acute financial stress and potential going-concern risk. Revenue base is extremely small relative to losses, indicating weak business scale and poor growth quality.
What is BQST's revenue and growth?
Bioquest Corp reported revenue of $31.0K.
Does BQST pay dividends?
Bioquest Corp does not currently pay dividends.
Where can I find BQST SEC filings?
Official SEC filings for Bioquest Corp (CIK: 0001568628) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BQST's EPS?
Bioquest Corp has a diluted EPS of $-0.06.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BQST a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Bioquest Corp has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BQST stock overvalued or undervalued?
Valuation metrics for BQST: ROE of N/A (sector avg: 15%), net margin of -398.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BQST stock in 2026?
Our dual AI analysis gives Bioquest Corp a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BQST's free cash flow?
Bioquest Corp's operating cash flow is $-18.6K, with capital expenditures of $10.4K. FCF margin is -93.5%.
How does BQST compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -398.5% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.03 (avg: 2).